Accession Number:



A Nanotechnology Solution for Early Detection of Micrometastatic Prostate Cancer After Radical Prostatectomy

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

Cedars-Sinai Medical Center

Personal Author(s):

Report Date:


Pagination or Media Count:



The overall objective of this research proposal is to conduct the initial development of a rapid circulating tumor cell-based blood test that can identify men with micrometastatic disease in order to facilitate patient selection for salvage radiotherapy. Aim 1 of this study was do perform a technical validation study and Aim 2 to embark upon testing of banked clinical specimens then to test the new assay in the setting of the NRG-GU-006 clinical trial salvage radiotherapy - apalutamide. In the first year of work we have begun a series of key technical validation studies while completing the sample collection from the now fully accrued NRG-GU-006 trial. Due to COVID-19 there were delays in progress but due to rapid clinical accrual and regearing of our studies, this effort is still on time.

Subject Categories:

  • Medicine and Medical Research
  • Anatomy and Physiology

Distribution Statement:

[A, Approved For Public Release]